Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04136171 · ClinicalTrials.gov registry record · Phase 3
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
A Phase 3 study of Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM), sponsored by Ionis Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 1,438
- Enrollment target
- 20
- Study locations
NCT04136171: Active Phase 3 study of Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM), sponsored by Ionis Pharmaceuticals.
NCT04136171 is a Phase 3 study of Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) that is active but no longer recruiting, run by Ionis Pharmaceuticals. The registered enrollment target is 1,438 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (86% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04136171, a Phase 3 study of Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM), is active but no longer recruiting, sponsored by Ionis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,438 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the efficacy of eplontersen compared to placebo in participants with ATTR-CM receiving available standard of care (SoC).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Eplontersen
Study Locations (20)
California
- Altman Clinical and Translational Research Institute Center for Clinical Research - La Jolla
- Cedars-Sinai Medical Center - Los Angeles
- University of California, San Francisco (UCSF) - Medical Center - San Francisco
- Stanford Hospital - Stanford
Illinois
- Northwestern University - Chicago
- The University of Chicago Medical Center - Chicago
- Loyola University Medical Center - Maywood
Louisiana
- Louisiana State University Health Sciences Center - New Orleans
- Tulane University Heart and Vascular Institute - New Orleans
- Ochsner Health System - New Orleans
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
- The George Washington Medical Faculty Associates - Foggy Bottom North Pavilion - Washington D.C.
Georgia
- Emory Heart and Vascular Center - Emory Clifton Campus - Atlanta
- Piedmont Heart of Fayetteville - Fayetteville
Arizona
- Mayo Clinic - Arizona - Phoenix
Colorado
- University of Colorado Hospital - Anschutz Medical Campus - Aurora
Florida
- Cleveland Clinic Florida - Weston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,438 participants |
| Start Date | 2020-03-13 |
| Est. Completion | 2026-08 |
| Phase | Phase 3 |
What the registry record for NCT04136171 still lists
NCT04136171 is an interventional study that assigns participants to a tested intervention. Its 1,438 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (86% higher).
The record links to 1 condition, with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04136171 names 20 study sites across 11 states, led by California, Illinois, Louisiana.
Frequently Asked Questions
What is clinical trial NCT04136171 about?
NCT04136171 is a clinical study titled "CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)". To evaluate the efficacy of eplontersen compared to placebo in participants with ATTR-CM receiving available standard of care (SoC).
What is the current status of trial NCT04136171?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,438 participants. The study started on 2020-03-13. Estimated completion is 2026-08.
What conditions does trial NCT04136171 study?
This clinical trial studies the following conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM).
What interventions are being tested in trial NCT04136171?
The interventions under investigation include: Placebo (DRUG), Eplontersen (DRUG).
Who is sponsoring clinical trial NCT04136171?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04136171 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04136171's enrollment target sits among peer trials
1,438 168th of 2000 higher than 1,833 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04754022 · 1,440 participants · NA
Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery
- NCT04989790 · 1,440 participants · NA
Clinical Effectiveness of the "PICU Up!" Multifaceted Early Mobility Intervention for Critically Ill Children
- NCT06122246 · 1,440 participants · NA
PRESSURE CHECK: Find Your Path to Better Health
- NCT06324318 · 1,440 participants · Phase 2
Parenting in 2 Worlds Multisite Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI